An Orally Bioavailable Oxime Ether Capsid Binder with Potent Activity against Human Rhinovirus
- 18 June 2003
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 46 (15) , 3181-3184
- https://doi.org/10.1021/jm0202876
Abstract
A series of capsid-binding compounds was screened against human rhinovirus (HRV) using a CPE based assay. The ethyl oxime ether 14 was found to have outstanding anti-HRV activity (median IC(50) 4.75 ng/mL), and unlike the equivalent ethyl ester compound 3 (Pirodavir), it has good oral bioavailability, making it a promising development candidate. Compound 14 illustrates that an oxime ether group can act as a metabolically stable bioisostere for an ester functionality.Keywords
This publication has 11 references indexed in Scilit:
- The Common ColdPediatric Annals, 1998
- Antirhino/Enteroviral Vinylacetylene Benzimidazoles: A Study of Their Activity and Oral Plasma Levels in MiceJournal of Medicinal Chemistry, 1997
- Antipicornavirus Drugs: Current StatusAntiviral Chemistry and Chemotherapy, 1997
- Intranasal pirodavir (R77,975) treatment of rhinovirus coldsAntimicrobial Agents and Chemotherapy, 1995
- The use of an algorithmic method for small molecule superimpositions in the design of antiviral agentsJournal of Computer-Aided Molecular Design, 1993
- TREATMENT OF THE PICORNA VIRUS COMMON COLD BY INHIBITORS OF VIRAL UNCOATING AND ATTACHMENTAnnual Review of Microbiology, 1992
- Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infectionAntimicrobial Agents and Chemotherapy, 1992
- In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activityAntimicrobial Agents and Chemotherapy, 1992
- A comparative test of fifteen compounds against all known human rhinovirus serotypes as a basis for a more rational screening programAntiviral Research, 1991
- Structural studies by nuclear magnetic resonance—XITetrahedron, 1967